Assenagon Asset Management S.A. Sells 48,500 Shares of CytomX Therapeutics Inc (NASDAQ:CTMX)

Assenagon Asset Management S.A. decreased its holdings in CytomX Therapeutics Inc (NASDAQ:CTMX) by 39.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,900 shares of the biotechnology company’s stock after selling 48,500 shares during the period. Assenagon Asset Management S.A. owned about 0.17% of CytomX Therapeutics worth $560,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Susquehanna International Group LLP bought a new stake in CytomX Therapeutics during the second quarter worth approximately $532,000. Voloridge Investment Management LLC bought a new stake in CytomX Therapeutics during the second quarter worth approximately $301,000. Nuveen Asset Management LLC bought a new stake in CytomX Therapeutics during the second quarter worth approximately $8,352,000. Victory Capital Management Inc. increased its stake in CytomX Therapeutics by 20.0% during the second quarter. Victory Capital Management Inc. now owns 1,985,990 shares of the biotechnology company’s stock worth $22,283,000 after acquiring an additional 330,460 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in CytomX Therapeutics by 16.2% during the second quarter. UBS Asset Management Americas Inc. now owns 28,564 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 3,974 shares during the last quarter. 78.50% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on CTMX. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, August 7th. BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. Nomura reissued a “buy” rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Mizuho reaffirmed a “buy” rating and set a $16.00 target price on shares of CytomX Therapeutics in a research note on Monday, August 12th. Finally, ValuEngine raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the stock. CytomX Therapeutics has an average rating of “Buy” and an average price target of $20.14.

CTMX opened at $6.97 on Wednesday. The stock has a market cap of $305.15 million, a price-to-earnings ratio of -3.43 and a beta of 0.68. The stock’s 50 day moving average price is $8.02 and its 200-day moving average price is $9.84. CytomX Therapeutics Inc has a one year low of $6.64 and a one year high of $19.75. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.66 and a current ratio of 4.66.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). The business had revenue of $9.01 million for the quarter, compared to the consensus estimate of $15.11 million. CytomX Therapeutics had a negative net margin of 158.05% and a negative return on equity of 77.05%. As a group, analysts predict that CytomX Therapeutics Inc will post -2.01 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Featured Article: What is a price target?

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.